[HTML][HTML] Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinib
S Mori - Transfusion and Apheresis Science, 2020 - Elsevier
Many biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic
DMARDs (tsDMARDs) are currently available as treatment options for rheumatoid arthritis …
DMARDs (tsDMARDs) are currently available as treatment options for rheumatoid arthritis …
Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis.
K Sonomoto, Y Tanaka - Nihon Rinsho Men'eki Gakkai Kaishi …, 2015 - europepmc.org
Recent advance in treatment of rheumatoid arthritis (RA) has been derived by biological
disease-modifying antirheumatic drugs (bDMARDs) targeting cytokines. A Jak inhibitor …
disease-modifying antirheumatic drugs (bDMARDs) targeting cytokines. A Jak inhibitor …
Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations
T Koike - Journal of Orthopaedic Science, 2015 - Springer
Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation due to unknown
causes. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) …
causes. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) …
THU0185 comparison of tofacitinib safety and efficacy in rheumatoid arthritis patients with inadequate response to conventional synthetic dmards, or to one or more …
C Charles-Schoeman, J Kremer, S Krishnaswami… - 2017 - ard.bmj.com
Background Tofacitinib is an oral JAK inhibitor for the treatment (tx) of rheumatoid arthritis
(RA). Studies have shown diminishing response to tx in RA patients (pts) when cycling …
(RA). Studies have shown diminishing response to tx in RA patients (pts) when cycling …
AB0485 Comparative efficacy of tofacitinib and biologic dmards in patients with rheumatoid arthritis with insufficient response to subcutaneous methotrexate in clinical …
EL Luchikhina, D Karateev, G Loukina, M Borisova… - 2018 - ard.bmj.com
Background Tofacitinib (TOFA)–the first registered member of the group of Janus-kinase
inhibitors–actively entered into practice. Some clinical trials show efficacy similar to …
inhibitors–actively entered into practice. Some clinical trials show efficacy similar to …
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
C Charles-Schoeman, G Burmester, P Nash… - Annals of the …, 2016 - ard.bmj.com
Objectives Biological disease-modifying antirheumatic drugs (bDMARDs) have shown
diminished clinical response following an inadequate response (IR) to≥ 1 previous …
diminished clinical response following an inadequate response (IR) to≥ 1 previous …
Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events
K Sonomoto, K Yamaoka, S Kubo, S Hirata… - …, 2014 - academic.oup.com
Objectives. To assess the effects of tofacitinib on T lymphocytes in RA patients with a special
focus on efficacy and infectious adverse events (iAEs). Methods. Forty-four RA patients …
focus on efficacy and infectious adverse events (iAEs). Methods. Forty-four RA patients …
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
K Ebina, T Hirano, Y Maeda, W Yamamoto… - Clinical …, 2021 - Springer
Objectives The aim of this multicenter, retrospective study was to clarify the retention rates of
sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis …
sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis …
THU0174 A Safety Analysis of Tofacitinib 5 mg Twice Daily Administered as Monotherapy or in Combination with Background Conventional Synthetic Dmards in A …
A Kivitz, B Haraoui, J Kaine, V Castellano, E Bananis… - 2016 - ard.bmj.com
Background Tofacitinib is an oral JAK inhibitor for the treatment of RA. In Phase 3 studies,
tofacitinib demonstrated safety and efficacy at 5 and 10 mg BID when used as monotherapy …
tofacitinib demonstrated safety and efficacy at 5 and 10 mg BID when used as monotherapy …
[PDF][PDF] A multicenter study of leukocytapheresis in rheumatoid arthritis
Y Ueki, A Sagawa, K Tanimura, A Yamada… - Clinical & …, 2007 - researchgate.net
CLIN AND EXP RHEUM 25/6 Page 1 Clinical and Experimental Rheumatology 2007; 25:
810-816. A multicenter study of leukocytapheresis in rheumatoid arthritis Y. Ueki1, A. Sagawa2 …
810-816. A multicenter study of leukocytapheresis in rheumatoid arthritis Y. Ueki1, A. Sagawa2 …